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Important classes of benign and malignant neoplasms are composed of melanocytic cells 
which produce a pigment called melanin. Benign nevi, which are non-malignant 
melanocytic lesions, can sometimes give rise to malignant melanoma. Melanoma can be a 
lethal melanocytic neoplasm, a deadly and aggressive form of skin cancer. Finding 
prognostic or diagnostic markers can be very useful to reduce the deaths caused by 
melanoma. Array Comparative Genomic Hybridization (aCGH), a cytogenetic technique, 
analyzes the whole genome or chromosome for detecting genetic aberrations/variations 
such as single nucleotide polymorphisms (SNPs) in a cancer.  formalin fixed paraffin 
embedded FFPE tissues are usually taken from suspected tumor tissues, fixed with 
formalin to preserve the protein and cytoskeletal structure and embedded in paraffin wax 
so that they can be cut and used for pathological diagnosis. These specimens are the 
starting material for extracting the DNA, but it can be quite challenging for getting DNA 
of good quality. Here we compared 27 samples extracted from FFPE tissues with three 
different extraction methods: phenol-chloroform isoamyl alcohol, Qiagen QIAamp FFPE 
iv 
 
kit, and adaptive focused acoustics (AFA) to see whether the method will have any effect 
on the DNA quality in the samples. We found that the AFA method showed better quality 
control (QC) results than other methods, where AFA showed increased amplicon length 
and decreased RAPD PCR failure rate. These were successfully hybridized to the 
microarrays and the data compared between methods. A total of 42 melanocytic nevi and 
21 benign nevi were analyzed by aCGH.  We found some novel SNPs and the genes 
associated with them, these genes are already shown to be involved in melanoma as well 
as in benign nevi. So, these findings can help to see whether the SNPs from benign nevi 
are predisposing to melanoma or if the SNPs themselves are causing the melanoma and 






The hypothesis of the project is that the quality of the DNA does have an effect on how 
successfully the samples can hybridize onto array CGH microarrays. Therefore, 
improving the quality of the DNA will improve the aCGH data to efficiently find SNPs 





1. Optimize the quality of extracted genomic DNA from formalin-fixed paraffin 
embedded tissues for DNA fragment length, yield, and PCR performance. 
2. Improve the performance of SNP 6.0 microarrays for FFPE DNA and generate 
raw array data. 
3. Detect the novel SNPs that predispose to malignant melanoma. 
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I.INTRODUCTION AND BACKGROUND  
 
 Melanoma is one type of skin cancer that is serious. This cancer occurs in melanocyte 
cells which are present in the skin like uvea of the eye and also it can occur in mouth, 
anal or genital areas and other organs inside the body like the intestines. The melanocytes 
are present in one of the layers of skin called epidermis where they produce a pigment 
called “melanin”. This melanin gives color to the skin based on how much is present in 
the skin, the more the melanin the darker the skin will be. Of all the skin cancers 
melanoma is least common (%2), yet it is the cause of most skin cancer-related deaths 
[2]. According to the American Cancer Society, in 2015 approximately 74,000 cases will 
be diagnosed in the US and approximately 10,000 people will die from this cancer. 
Benign nevi which are noncancerous (moles) and non-metastatic when exposed to risk 
factors like UV light sometimes develop into cancerous tumors and spreads to  the lymph 
nodes, blood vessels and finally to other organs like the lungs, brain etc. and become 
metastasized. It is a rare cancer and curable if detected in the early stages [3] but is 
deadly once metastasized everywhere. The 5 year survival rate shows that depending on 
the stage of the cancer when diagnosed,  it can be as high as 98% when it does not spread 
, it decreases to 67% if it spreads to other lymph nodes  and to less than 15%  if it spreads 
to other organs [2]. People with risk factors like red hair, fair skin and blue eyes are at 




associated with melanoma. Melanocytes can give rise to both benign melanocytic nevi 
and malignant melanoma. A high risk of melanoma is found in if the people having a 
family history of the disease [5]even though it is otherwise rare. Some studies have 
shown that those who had familial melanoma, and so many benign melanocytic nevi 
there is strong chance that  the nevi can give rise to the melanoma[6-9]. 
Early diagnosis of melanoma is very important for treatment. Histopathologic study of 
skin biopsies by dermatopathologists is considered as the standard approach to diagnose 
skin lesions with the help of microscope [10].  Cellular anatomy of a tumor revealed by 
Hematoxylin and Eosin (H&E) staining which is one of the most widely used standard 
method to diagnose the suspected tumors. This staining method helps in showing staging 
and grading of the tumor taken from the skin biopsies. These are developed to determine 
the treatment and prognosis of malignant neoplasms. Staging tells the condition of cancer 
depending on whether the size or extension of invasion is large or not, if the invasion is 
spread to lymph nodes or not and tells the presence/absence of distant metastases. Stage 0 
shows that the melanoma is in situ, stage I, II and III show that the tumor size is large and 
spread to other organs like lymph nodes and/or nearby organs to primary tumor site, stage 
IIII shows that the cancer has already spread to distant organs [11] On the other hand, 
grading is dependent upon the microscopic observation of the malignant neoplasms in 
H&E staining. It tells about the abnormality of tumor tissues and look under microscope. 
The higher the grading the less differentiation of cells and the worse the behavior of 
malignant neoplasms and vice versa, since benign neoplasms are well differentiated and 
differentiated cells have the resemblance of the original cells [12]. However, 




differentiate benign nevi from malignant melanoma, because some melanocytic tumors 
share common histopathological features that are overlapping. Some benign melanocytic 
nevi, because of secondary changes, show abnormal characteristics that are mostly 
associated with the melanoma diagnosis. Therefore the histopathologic diagnosis of these 
tumors can be a challenge [13]. The histopathologic examination is sometimes not 
enough to make the diagnostic decisions. Several studies reported the uncertainty and 
discordance in diagnosing melanoma from benign nevi among the dermatopathologists 
who are experts in this area [13-19]. The ambiguity of melanoma can lead to 
misdiagnosis.  Over diagnosis makes more stress, unnecessary surgeries and cost of 
medical insurance. On the other hand, under diagnosis can result in negligence of the 
disease[3] and can be deadly but curable if detected in the early stages. Because of this, 
molecular diagnostic techniques have become ancillary tools to aid diagnosis of 
melanocytic lesions. These techniques have shown to be useful in identifying the 
melanocytic lesions and the presence of melanoma.  
BRAF is a serine/threonine protein kinase involved in the MEK/ERK pathway. Mutations 
in this protein; BRAF V600E (about 80%) and BRAF V600K (about 5-30%) are most 
prevalent in melanoma [20]. Vemurafenib is an inhibitor of mutant BRAF activity.  
Patients in late stage melanoma when treated with Vemurafenib have improved survival 
chances [21].  These mutations can occur later in life as oncogene, causing cancer and is 
seen in both melanoma and rarely in nevi. To know the existence of these mutations, 
histopathological observations are not enough. Molecular diagnostic methods like 
Immunohistochemistry (IHC)  are available as adjunct techniques for diagnosing 




expression level.  Some of the markers used for IHC include: S-100, HMB-45, Mitf, 
Melan-A, and tyrosinase for diagnosing melanoma [25] and also Ki-67 which is used as 
mitotic index to determine the stage of the cell tumor [26]. S-100 protein is a calcium 
binding protein and it has association with malignant melanoma because the higher  
expression of it leads to  cancer cell proliferation, differentiation, tumor metastases, cell 
invasion, cell growth and apoptosis [27]  S100 protein monoclonal antibody thus can help 
in diagnosing melanoma from tumors by reacting with the antigens in the melanocytic 
tumors with doubtful histological origin and tells whether the presence of tumors is in 
lymph nodes or other tissues [27] [28]. HMB-45 is a monoclonal antibody that reacts to 
antigens in the melanocytic tumors only. It has a good specificity for identifying 
malignant melanomas thus avoiding poor diagnosis [29, 30]. Mitf is a transcription factor 
involves in the regulation of pathways of cells like melanocytes, it regulates the 
production of melanin in melanocytes. Any mutation in Mitf leads to melanoma [31] . 
Recently Mitf immunohistochemical stain is used in identifying metastatic melanoma 
effectively [32]. Melan-A is a protein antigen found in the melanocytes. The melan-A 
marker is found to be useful in diagnosing melanoma [33] [34]. Ki-67 is a protein 
involved in cell proliferation and the marker can help in identifying the cell stage 
especially during mitosis to determine the growth of the tumor [26]. But all these markers 
still lack a certain group of lesions indeterminate even to expert pathologists. 
Additionally, cytogenetic techniques have emerged to diagnose melanocytic lesions. 
Fluorescence in situ hybridization (FISH) is one of these techniques that have gained use 
in melanoma diagnostics [10, 35-37]. FISH recently has a set of new four probes 




are being used to identify the malignant melanomas with increased specificity and 
sensitivity [13]. These 4 probe set were selected as best for distinguishing benign nevi 
from malignant melanoma [38, 39]. RREB1 also known as Ras-responsive element 
binding protein 1 (RRE) and Raf responsive zinc finger protein is a transcription factor 
that binds to RRE and leads to increased Ras/Raf activity. MYB is another transcription 
factor. CCND1 is cyclin D1 proto oncogene which plays an important role in G1-S phase. 
CEP6 is used as a control for the ploidy status for chromosome 6. When tested with these 
4 genes in so many studies, they were able to distinguish benign from melanoma in most 
of the cases, thus this 4 probe panel became significant in diagnosing the melanoma. 
However FISH has its own limitations that it cannot detect smaller abnormalities in the 
chromosome, cannot be used for screening the entire chromosomes and is loci specific 
[40, 41]. Another cytogenetic technique, comparative genomic hybridization (CGH) has 
become a useful technique since it can look into the entire genome to look for 
abnormalities. CGH has been a very useful technique in cancer research [42] and in 
diagnosing melanoma [43]. Even though it has  the ability to distinguish the tumors it has 
its own disadvantages of having  very less  resolution of 3-10 Mb [44] which means its 
inability to detect smaller regions in copy number changes and certain chromosomal 
regions involved in losses and gains [40] across the genome. So this lead to another 
technique called array CGH with higher resolution to look into the entire genome to 
analyze abnormalities on entire genome and/or chromosome of our interest. Array 
comparative genomic hybridization (aCGH) can detect simultaneously single nucleotide 
polymorphisms (SNP), is a DNA sequence variation occurring in which a single nucleotide (A, 




within the paired chromosomes. Copy number variations that have alterations of DNA 
across the genome with more than normal number of segments of DNA (gene) either 
deleted or amplified can also be detected in a single experiment. aCGH is a highly 
specific, fast, and high throughput technique. It can be used to distinguish between 
benign nevi and malignant melanoma by using FFPE tissues [45]. It can be used  on 
variety of sample types such as paraffin embedded [46], frozen [47], cell lines [48] , 
blood samples [49] and has major applications in cancer [50]. It has shown promising 
results for diagnosing many cancers [50]. An important advantage is that it requires only 
a minimum number of cells from FFPE tissue sections [45].  
 
Because of its high resolution, array CGH is being used to identify the most frequent 
genomic variants called SNP. SNPs can affect the function of genes and SNPs act as 
biological markers in finding the genes involved with diseases [51]. Studies have shown 
that the SNPs are useful in studying cancer [52, 53].  Benign nevi are associated with an 
increased risk of melanoma [54]. Therefore it is important to look into both benign and 
melanoma to find the actual SNPs associated with melanoma. Some of the genes that are 
associated with SNPs and are involved in melanoma are BRAF [55], GNAQ [56], 
GNA11 [57], PLA2G6, MTAP and IRF4[54]. We are interested in SNPs and genes that 
are associated with melanoma. 
 
Array CGH has its own limitations.  It requires good quality and a sufficient quantity of 
DNA to successfully hybridize to the microarrays.   Getting good quality DNA from 




used as starting material in our research. Because it has many advantages such as stability 
for decades [58], can be used for routine histopathologic diagnosis of diseases [58], easy 
handling and especially used for downstream analysis [59]  At the same time DNA 
obtained from biopsied tissues are small and often irreplaceable. We have to extract DNA 
by an efficient extraction method.  While FFPE tissues are stable for decades [60], this 
preservation presents significant challenges.  The process of fixation with formalin, 
embedding and handling the tissues, should be done carefully in order to improve the 
quality of the nucleic acids for molecular testing [61].  Formalin treatment cross-links 
biological molecules such as DNA and proteins [61] so the nuclear material will get 
trapped and prevent from breakage which later has to be reverse cross linked to retrieve 
the nuclear material. Also, since longer nucleic acids like RNA and DNA, are fragmented 
in the preservation process, it leads to poor performance in downstream analyses [62, 63].  
To optimize utility of nucleic acids from FFPE specimens for aCGH, we must reverse 
these cross links and avoid further degradation during the DNA extraction process. 
Inefficient tissue rehydration results in poor reverse cross linking and thereby less quality 
of DNA, so it is very important to rehydrate the tissue during paraffin removal.  Several 
previous studies have compared protocols for DNA extraction from FFPE tissues, with 
varying results.  Senguven et al. compared several variations on the CTAB method that 
used CTAB to disrupt the cellular membranes  and a hot alkali method that lyse the 
genetic material with alkaline solution,  and these both methods are  compared with the 
Qiagen FFPE DNA kit [64], a solid-phase extraction that uses silica gel membrane in the 
spin column to trap the nucleic acids and eluted later with buffer.  They found that the 




more than 50 years old.  There is some controversy between laboratories, however, as 
other studies have compared the Qiagen kit with phenol-chloroform. This is a liquid-
liquid extraction method separates the proteins in organic phase and DNA in the aqueous 
phase. They found either the columns [65] or the phenol method [66] to be superior in 
yield and amplifiability.  Other methods less frequently used, not measured in our study 
include the Maxwell 16 method by Promega (Mannheim, Germany). In this method, the 
nucleic acids bound to magnetized silica particles and later eluted. This extraction method 
was shown to perform well against other automated Qiagen kits [67], and the Chelex 
bead method (Bio-Rad, Berkeley, California). This is an ion exchange resin that 
inactivates the nucleases by removing magnesium and thus protects DNA for the PCR. 
Chelex bead method has been used with some success in manual or automated 
extractions from FFPE tissues [68].  A small number of studies have shown that the DNA 
obtained by a recent sonication-based method called adaptive focused acoustics (AFA) is 
more amenable to next generation sequencing than DNA from other methods, resulting in 
greater coverage of the genome and facilitating easier assembly and alignment [69-71]. 
AFA is also a solid-phase extraction but it uses acoustic energy to de-paraffinize the 
tissues. To our knowledge, ours is the first study to compare AFA for use in aCGH.  
Here, we compared three different extraction methods: phenol-chloroform extraction, 
commercial (Qiagen) column-based purification, and adaptive focused acoustic (AFA) 
extraction, to see which works best to retrieve DNA for aCGH.  Quantity and quality 
measures are considered for each extraction method. Nanodrop concentrations which are 
based on spectophotometric absorbance at 260 nm are measured and also the 260/230 and 




concentrations are not accurate because the absorbance at 260 nm can measure not just 
dsDNA, so we measured qubit concentrations, since fluorescent dye in qubit only binds 
to the dsDNA and gives accurate concentrations of our samples. Next, we performed 
RAPD PCR that amplifies DNA template randomly to see whether the DNA in our 
samples are degraded or not by doing gel electrophoresis. Finally we measured RAPD 
PCR failure rates in each method, samples that have not shown enough amplicon length 
(< 300base pair length) are considered as failure and will be removed. 
 Once we got good quality of DNA then samples were hybridized them on to the 
microarrays successfully. These microarray data were analyzed using Genotyping 
Console (GTC) for genotyping analysis to get SNPs list. Then the SNPs were filtered and 
analyzed using Partek Genomics Suite (PGS). Once got the SNPs and associated genes 
list, used Ingenuity Pathway Analysis (IPA) to confirm our findings with the curated 
literature in IPA about the genes and SNPs known to be involved with melanoma. We 
found total of 8 genes along with the associated SNPs. Along with 8 genes known to be 
involved in melanoma, their associated novel SNPs were identified in genes that are 
known to be involved in melanoma. 
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II. METHODS AND MATERIALS 
 
 Specimen Collection and preparation: 
After IRB review, the FFPE tissue blocks were collected from a national 
dermatopathology laboratory (Dermatopathology Laboratory of Central States, DLCS, 
Dayton, OH).  They were stored in a temperature-controlled room. First we retrieved the 
clinical data and health records of the patients using laboratory information management 
software (Intellipath) at DLCS.  The biopsy specimens collected are from 2007 and 2004, 
making them 8 or 11 years old. Patients ranged in age from 16 to 75 years.  Based on the 
clinical data, we selected specimens that are unambiguously benign or melanoma and of 
sufficient size to not exhaust the tissue block during analysis. 
10µm thickness sections were taken from FFPE tissue blocks using a microtome with 
disposable blades at DLCS. To avoid contamination between blocks, care was taken by 
wearing gloves and using new blades for every specimen. Sections were slightly warmed 
in the water bath to facilitate mounting onto slides.  The slides were then air dried 
overnight. The first and last slides were kept for H&E staining and examined under 
microscope to confirm that the sections on the slides have the region of interest (benign 
melanocytic nevi or melanoma cellular material). The tissues in the sections were 
scrapped off avoiding as much paraffin as possible using sterile scalpel blades and 
collected into 1.5 ml centrifuge tubes for extracting the DNA. The number of sections 





DNA isolation from FFPE tissues: 
For DNA isolation three extraction methods were used: Qiagen QIAamp DNA FFPE 
tissue kit, phenol-chloroform isoamyl alcohol extraction and Adaptive Focused Acoustics 
(AFA) - based extraction using the Covaris truXTRAC FFPE DNA kit. 
Qiagen method: 
The protocol suggested by Qiagen QIAamp DNA FFPE tissue kit (QIAGEN 
GmbH, D-40724 Hilden) is as follows: 
            1. Using a scalpel, trim excess paraffin off the sample block.  
2. Cut up to 8 sections 5–10 µm thick. If the sample surface has been 
exposed to air, discard the first 2–3 sections.  
3. Immediately place the sections in a 1.5 or 2 ml micro centrifuge tube 
and add 1 ml xylene to the sample. Close the lid and vortex vigorously for 
10 sec. 
 4. Centrifuge at full speed for 2 min at room temperature (15–25°C).   
5. Remove the supernatant by pipetting. Do not remove any of the pellet.  
6. Add 1 ml ethanol (96–100%) to the pellet, and mix by vortexing. The 
ethanol extracts residual xylene from the sample.  




8. Remove the supernatant by pipetting. Do not remove any of the pellet. 
Carefully remove any residual ethanol using a fine pipet tip. 
 9. Open the tube and incubate at room temperature or up to 37°C. 
Incubate for 10min or until all residual ethanol has evaporated.  
10. Resuspend the pellet in 180 µl Buffer ATL. Add 20 µl proteinase K, 
and mix by vortexing.  
11. Incubate at 56°C for 1 h (or until the sample has been completely 
lysed). 
12. Incubate at 90°C for 1 h. The incubation at 90°C in Buffer ATL 
partially reverses formaldehyde modification of nucleic acids. Longer 
incubation times or higher incubation temperatures may result in more 
fragmented DNA. If using only one heating block, leave the sample at 
room temperature after the 56°C incubation until the heating block has 
reached 90°C.  
13. Briefly centrifuge the 1.5 ml tube to remove drops from the inside of 
the lid. If RNA-free genomic DNA is required, add 2 µl RNase A (100 
mg/ml) and incubate for 2 min at room temperature before continuing with 
step 14. Allow the sample to cool to room temperature before adding 
RNase A.  
14. Add 200 µl Buffer AL to the sample, and mix thoroughly by 




by vortexing. It is essential that the sample, Buffer AL, and ethanol are 
mixed immediately and thoroughly by vortexing or pipetting to yield a 
homogeneous solution. Buffer AL and ethanol can be premixed and added 
together in one step to save time when processing multiple samples. A 
white precipitate may form on addition of Buffer AL and ethanol. This 
precipitate does not interfere with the QIAamp procedure. 
15. Briefly centrifuge the 1.5 ml tube to remove drops from the inside of 
the lid.  
16. Carefully transfer the entire lysate to the QIAamp MinElute column 
(in a 2 ml collection tube) without wetting the rim, close the lid, and 
centrifuge at 6000 x g (8000rpm) for 1min.Place the QIAamp MinElute 
column in a clean 2ml collection tube, and discard the collection tube 
containing the flow-through. If the lysate has not completely passed 
through the membrane after centrifugation, centrifuge again at a higher 
speed until the QIAamp MinElute column is empty. 
17. Carefully open the QIAamp MinElute column and add 500 µl Buffer 
AW1 without wetting the rim. Close the lid and centrifuge at 6000 x g 
(8000 rpm) for 1 min. Place the QIAamp MinElute column in a clean 2ml 
collection tube, and discard the collection tube containing the flow-
through.  
18. Carefully open the QIAamp MinElute column and add 500 µl Buffer 




(8000 rpm) for 1 min. Place the QIAamp MinElute column in a clean 2ml 
collection tube, and discard the collection tube containing the flow-
through. Contact between the QIAamp MinElute column and the flow-
through should be avoided. Some centrifuge rotors may vibrate upon 
deceleration, resulting in the flow-through, which contains ethanol, 
coming into contact with the QIAamp MinElute column. Take care when 
removing the QIAamp MinElute column and collection tube from the 
rotor, so that low-through does not come into contact with the QIAamp 
MinElute column. 
19. Centrifuge at full speed (20,000 x g; 14,000 rpm) for 3 min to dry the 
membrane completely. This step is necessary, since ethanol carryover into 
the eluate may interfere with some downstream applications.  
20. Place the QIAamp MinElute column in a clean 1.5 ml micro centrifuge 
tube (not provided), and discard the collection tube containing the flow-
through. Carefully open the lid of the QIAamp MinElute column and 
apply 20–100 µl Buffer ATE to the center of the membrane. 
Important: Ensure that Buffer ATE is equilibrated to room temperature. If 
using small elution volumes (<50 µl), dispense Buffer ATE onto the 
center of the membrane to ensure complete elution of bound DNA. 
QIAamp MinElute columns provide flexibility in the choice of elution 




downstream application. The volume of elute will be up to 5 µl less than 
the volume of elution solution applied to the column.  
21. Close the lid and incubate at room temperature for 1 min. Centrifuge at full speed 
(20,000 x g; 14,000 rpm) for 1 min, incubating the QIAamp MinElute column loaded 
with Buffer ATE for 5min at room temperature before centrifugation generally increases 
DNA yield.  
The original protocol for the Qiagen FFPE DNA Tissue kit, modified by previous student 
in the lab (Sameep Naik), is as follows:  
1. Took 10µm thickness sections and Incubate tissue sample at 60˚C in water bath for 30 
minutes.  
2. Wash the tissue in micro centrifuge tube with 1 ml of 100% xylene and vortex, 
centrifuge at 20,000xg for 5 minutes, and then remove supernatant. 
3. Wash tissue in 500µl of 100% ethanol, vortex and centrifuge at 20,000xg for 3 minutes 
then remove supernatant. 
4. Wash tissue in 500µlof 75% ethanol, vortex and centrifuge at 20,000xg for 3 minutes 
then remove supernatant. 
5. Wash tissue in 500µl of 50% ethanol, vortex and centrifuge at 20,000xg for 3 minutes 
and then remove supernatant. 
6. Allow tissue to dry before processing. 




8. Add 100µl proteinase K, mix by vortexing. 
9. Incubate overnight (8-12 hours, never longer than 16 hours) at 56˚C. 
10. Add 400µl buffer AL to the sample and mix by inversion. 
11. Incubate at 70˚C for 10 minutes. 
12. Add 400µl ethanol to the sample and mix by inversion. 
13. Pipet mixture into DNeasy Mini Spin Column then centrifuge at 6000xg for 1 minute. 
Discard the flow through. 
14. Add 500µl wash buffer AW1, then centrifuge at 6000xg for 1 minute. Discard the 
flow through. 
15. Add 500µl wash buffer AW2 then centrifuge at 6000xg for 1 minute. Discard the 
flow through. 
16. Add 500µl wash buffer AW2 again, then centrifuge at 6000xg for 1 minute. Discard 
the flow through. 
17. Replace flow through tube with clean tube, then centrifuge at 20,000xg for 3 minutes 
to remove any residual ethanol from the spin column. 
18. Replace flow through tube with the clean micro centrifuge tube. 
19. Add 100µl buffer ATE, incubate at room temperature for 5 minutes. 
20. Centrifuge at 20,000xg for 1 minute. 




1. Cut 24 FFPE sections of 10 µm thickness for each DNA extraction.  
2. Incubate tissue samples in water bath at 60˚C for 30 minutes. 
3.  Wash tissues in micro centrifuge tube twice in 1 mL xylene, vortex and centrifuge at 
20,000xg for 3 minutes each time. 
4. Wash tissues in a descending concentration of ethanol (100, 75%, and then 50%), each 
time vortex and centrifuge at 20,000xg for 3 minutes and then remove supernatant.  
5. Allow tissues to dry in the micro centrifuge tubes completely before proceeding to next 
step. 
6.  Add 300 L Qiagen buffer ATL plus 40 L proteinase K (20mg/mL, 5 PRIME Inc., 
Gaithersburg, MD, USA) to dried tissue and mix by vortexing, incubate overnight for 
first 24 hours. 
7.  Then add an additional 30 L proteinase K at 24 hours and another 30 L at 48 hours.  
8.   After 72 hours digestion, add 400µl buffer AL to the sample, mix by inversion (never 
vortex after overnight incubation). 
9. Incubate at 70˚C for 10 minutes. 
10. Add 400µl ethanol to the sample and mix by inversion. 
11. Pipet sample mixture into were Qiagen DNeasy Mini Spin Columns, then centrifuge at 
6000xg for 1 minute. Discard the flow through. 
12.  Add 500µl wash buffers AW1 and AW2 one by one, each time centrifuge at 6000g for 1 
minute and discard the flow through.   





14.  Replace flow through tube with clean tube, then centrifuge at 20,000xg for 3 minutes to 
remove any residual ethanol from the spin column. 
15.  Replace flow through tube with the clean micro centrifuge tube. 
16.  Add 100µl buffer ATE, incubate at room temperature for 5 minutes. 
17.  Centrifuge at 20,000xg for 1 minute. 
Phenol-chloroform-isoamyl alcohol extraction method: 
Phenol-chloroform-isoamyl alcohol 25:24:1 (Fisher Scientific, Fair Lawn, New Jersey, 
USA) was used as described in Isola et al. The protocol is as follows: 
1. Twenty to thirty 5µ- sections were deparaffinized in eppendorf tubes (2 
x 1 ml xylene for 10 minutes each and 2 x 1 ml 100% ethanol for 10 
minutes each).2. After air drying at room temperature, samples were 
suspended in 1 ml DNA extraction buffer (0.3 mg/ml proteinase K 
(Sigma, St. Louis, MO), 100 mmol/L NaCI, 10 mmol/L Tris-HCI pH 8, 25 
mmol/L EDTA pH 8, and 0.5% sodium dodecyl sulfate) and were 
incubated with shaking at 55˚C overnight.  
3. Additional proteinase-K (10µl from 20 mg/ml stock solution) was 
added 24 hours and 48 hours later for a total incubation time of 72 hours.  
4. A 500µl sample mixed with 500 µl phenol chloroform isoamyl 
(Amresco, Solon, OH) was incubated at room temperature for 10 minutes 




5. DNA in the top layer was collected and precipitated with 250 µl of 7.5 
mol/L ammonium acetate and 1 ml of ice-cold 100% ethanol.  
6. DNA was pelleted by centrifugation (14,000 rpm for 20 minutes). 
7. Glycogen (0.1 mg/ml; Sigma) was added before centrifugation as a 
carrier to increase the volume of the pellet. 
8. DNA was dissolved overnight in 20 to 40 µl of TE buffer (10 mmol/L 
Tris, 1 mmol/L EDTA). 
We used the same protocol but with some modifications: 
1. 24 sections of 10 m thickness were used from each FFPE sample. FFPE sections were 
scraped off of the air-dried slides using sterile scalpel blades and collected into 1.5 mL 
micro centrifuge tubes.   
2. Add 1ml of xylene to each tube, vortex and incubate for 10 min, centrifuge for 5 min at 
20,000 x g. Discard the supernatant. 
3. Repeat the above step again. 
4. Add 1ml of 100% ethanol, vortex, incubate for 10 min, centrifuge for 3 min at 20,000 x 
g. Discard the supernatant. 
5. Repeat the above step. 
6. Add 1ml of 75% ethanol, vortex, incubate for 10 min, centrifuge for 3 min at 20,000 x g. 
Discard the supernatant. 
7. Air dry the tubes at room temperature by inverting them on a tissue. 




9. Keep tubes now on water bath shaking incubator at 57˚C (control temperature) or at 70˚C 
(Stat temperature).Adjust the speed to 3-3½ rpm. 
10. Keep checking the water level in the shaker regularly. 
11. Add 10µl proteinase k to each tube after 24 hours and vortex very lightly. 
12. Add 10µl proteinase k to each tube after 48 hours and vortex very lightly. 
13. After 72 hours take out the tubes and keep them at 95˚C for 40 min and bring them to 
room temperature. 
14. Add 500µl of each tube and 500µl of phenol chloroform to one tube (shake the 
chloroform) and vortex. 
15. Centrifuge at 20,000g for 1 min. 
16. 2 layers will be formed in each tube, flip each tube for 5 sec and let them sit for 5 min at 
room temperature. 
17. Centrifuge at 20,000rcf for 10 min at 4˚C. 
18. Transfer the top aqueous layer that has DNA to new tube. 
19. Add chloroform approximately the amount of DNA the new tube has (for 100ul of DNA 
amount add 100ul of chloroform), flip the tube, incubate for 5 min at room temperature 
and centrifuge at 20,000rcf for 10 min. 
20. Using pipette take put the top layer, put them in new tube. Discard the organic solvent by 
dumping them in the container in SASH. 
21.  Add 1ml of ice cold ethanol to each tube and then add 250µl of ammonium acetate  







1. Wash the pellet by adding 500µl 70% ethanol, invert several times, and spin at maximum 
speed at 4˚C for 5 min.  
2. Aspirate carefully. Dry the pellet completely(~5-10min) 
3. Pre-warm the TE buffer (Tris 10Mm, EDTA 1Mm pH8.0) at 55˚C and add 40µl buffer to 
each tube. 
4. Incubate at room temperature for overnight. 
Adaptive focused acoustics: 
The third extraction method is adaptive focused acoustics (AFA) technology.  This was 
performed using FFPE tissues with 10 m thickness for 8-10 sections. The extraction was 
performed according to the protocol suggested by Covaris (Woburn, MA, USA) in the 
truXTRAC FFPE DNA kit.  Slides were warmed on a heat block to 37 °C for 30 seconds.  
FFPE tissue was then scraped from the slides, avoiding paraffin, using Covaris 
SectionPicks. Sections were collected into Screw-Cap microTUBES by using FFPE 
SectionPicks provided by Covaris.  AFA was performed per manufacturer’s instructions 
(“protocol C”) on a Covaris M220 Focused-Ultrasonicator. The protocol is as follows: 
1. Open microTUBE Screw-Cap, add 100 µl Tissue SDS Buffer into 
microTUBE and load FFPE tissue (section or core). Affix Screw-Cap 
back in place.  
2. Process the sample using the settings provided in the protocol to dissociate 




process it is normal for the solution to turn milky white as the paraffin is 
emulsified.  
 
                 Paraffin removal and tissue rehydration settings 
 
 
                              Proteinase K mixing settings 
3. Open Screw-Cap microTUBE, add 20 µl of Proteinase K solution to the 
sample and affix Screw-Cap back in place. 
4.  Process the sample using the settings provided to properly mix Proteinase 
K with the sample.  
5. Protein digestion at 56°C. Insert the required number of Heat Block 
microTUBE Adapters into a Heat Block and set the temperature to 56°C.  
6.  Load the microTUBE into the adapter once the heat block has reached its 
set point.  
7.  An incubation time of 1 hour at 56°C is sufficient for sections 10 µm or 
less in thickness; 12-hour (i.e. overnight) incubation should be used for 
larger samples, such as 25 µm sections and cores. If the digestion is 




incubate for 1 more hour. Here homogenized tissue was digested for 2 
hours instead of 1 hour in proteinase K provided by Covaris kit. 
8.  Incubate the samples at 80°C for 1 hour to reverse formaldehyde 
crosslinks. 
9.  Insert the required number of Heat Block microTUBE Adapters into a 
Heat Block and set the temperature to 80°C. Load the microTUBE into the 
adapter once the heat block has reached its set point. 
10.  If using the same heat block for both the 56°C & 80°C incubations, the 
microTUBE should be stored at room temperature until the heat block 
reaches 80°C.  
11. Transfer the sample to a clean 1.5 ml micro centrifuge tube.  
Optional: The sample can be treated with RNase A to remove RNA before 
DNA purification. Add 5µl of RNase A solution and incubate for 5 
minutes at room temperature.  
Then DNA purification is as follows: 
Set heat block to 70°C and preheat the required volume of Buffer BE in a 
1.5mL microfuge tube: (number of samples x 100 µl x 1.1)  
1. Add 140 µl Buffer B1 to your sample and vortex thoroughly.  
2. Add 160 µl ethanol (>96%) to the sample and vortex thoroughly. 
3. Centrifuge at 10,000 x g for 2 minutes at room temperature. After 
centrifugation much of the paraffin will have formed a white layer, 
floating on top of the liquid.  




 5. While holding the sample tube at about the same angle as in the rotor, 
use a pipette to slowly recover the liquid layer, and transfer to the column. 
Transfer of a small amount of paraffin particles to the column is 
acceptable and will not interfere with the DNA purification.  
6. Spin the assembly at 11,000 x g for 1 minute.  
7. Discard the flow-through and place the Column back in the Collection 
Tube.  
8. 1 st wash: Add 500 µl Buffer BW. Spin the assembly at 11,000 x g for 1 
minute.  
9. Discard the flow-through and place the Column back in the Collection 
Tube. 
 10. 2 nd wash: Add 600 µl Buffer B5. Spin the assembly at 11,000 x g for 
1 minute.  
11. Discard the flow-through and place the column in a new Collection 
Tube  
 12. Dry column: Spin the assembly at 11,000 x g for 1 minute. 
13. Elute DNA - 1 st step: Place the Purification Column into a new 1.5 ml 
microfuge tube and add 50 µl pre-warmed Buffer BE (70 °C) to the center 
of the column. Incubate at room temperature for 3 minutes. Spin the 
assembly at 11,000 x g for 1 minute.  
14. Elute DNA – 2 nd step: Add a second aliquot of 50 µl pre-warmed 
Buffer BE. Incubate again at room temperature for 3 minutes. Spin the 




15. DNA is eluted in 100 µl Buffer BE. 
We followed the same protocol but we changed the paraffin removal treatment time from 
300sec to 510sec .For this extraction method the DNA was concentrated by speedvac 
without heat in order to get enough concentration for the SNP 6.0 protocol. 
 Quality control: 









 ratios.  Clean the Nanodrop first by 1.5 µl water 
and then by 1.5 µl of buffer, the type of buffer depends on which extraction method the 
DNA sample was eluted. Now load 1.5 µl of DNA sample on to the Nanodrop to check 
the concentration and ratios.  
  Qubit:  
For a more accurate quantitation, the Qubit® dsDNA BR Assay Kit (Thermo Fisher 
Scientific, Waltham, MA) was used to check the concentrations of dsDNA for all 
samples.  
We followed the manufacturer’s protocol. The protocol is as follows: 
1. Set up the required number of 0.5-mL tubes for standards and samples. 
The Qubit® dsDNA BR Assay requires 2 standards.  
Note: Use only thin-wall, clear, 0.5-mL PCR tubes. Acceptable tubes 




2. Label the tube lids. Note: Do not label the side of the tube as this could 
interfere with the sample read. Label the lid of each standard tube 
correctly. Calibration of the Qubit® fluorometer requires the standards to 
be inserted into the instrument in the right order.  
3. Prepare the Qubit® working solution by diluting the Qubit® dsDNA 
BR Reagent 1:200 in Qubit® dsDNA BR Buffer. Use a clean plastic tube 
each time you prepare Qubit® working solution. Do not mix the working 
solution in a glass container. Note: The final volume in each tube must be 
200 µL. Each standard tube requires 190 µL of Qubit® working solution, 
and each sample tube requires anywhere from 180–199 µL. Prepare 
sufficient Qubit® working solution to accommodate all standards and 
samples. For example, for 8 samples, prepare enough working solution for 
the samples and 2 standards: ~200 µL per tube in 10 tubes yields 2 mL of 
working solution (10 µL of Qubit® reagent plus 1990 µL of Qubit® 
buffer). 
 4. Add 190 µL of Qubit® working solution to each of the tubes used for 
standards.  
5. Add 10 µL of each Qubit® standard to the appropriate tube, then mix 
by vortexing 2–3 seconds. Be careful not to create bubbles. Note: Careful 
pipetting is critical to ensure that exactly 10 µL of each Qubit® standard is 




6. Add Qubit® working solution to individual assay tubes so that the final 
volume in each tube after adding sample is 200 µL. Note: Your sample 
can be anywhere from 1–20 µL. Add a corresponding volume of Qubit® 
working solution to each assay tube: anywhere from 180–199 µL.  
7. Add each sample to the assay tubes containing the correct volume of 
Qubit® working solution, then mix by vortexing 2–3 seconds. The final 
volume in each tube should be 200 µL.  
8. Allow all tubes to incubate at room temperature for 2 minutes.  
Reading standards and samples procedure are as follows: 
1. On the Home screen of the Qubit® 2.0 Fluorometer, press DNA, then 
select dsDNA Broad Range as the assay type. The “Standards” screen is 
displayed. Note: If you have already performed a calibration for the 
selected assay, the instrument prompts you to choose between reading new 
standards and running samples using the previous calibration. If you want 
to use the previous calibration, press No and skip to step 5. Otherwise, 
continue with step 2.  
2. On the Standards screen, press Yes to read the standards.  
3. Insert the tube containing Standard #1 into the sample chamber, close 
the lid, then press Read. When the reading is complete (~3 seconds), 




4. Insert the tube containing Standard #2 into the sample chamber, close 
the lid, then press Read. When the reading is complete, remove Standard 
#2. When the calibration is complete, the instrument displays the Sample 
screen.  
5. Insert a sample tube into the sample chamber, close the lid, then press Read. When the 
reading is complete (~3 seconds), remove the sample tube. The instrument displays the 
results on the Sample screen. The value displayed corresponds to the concentration after 
your sample was diluted into the assay tube. To find the concentration of your original 
sample, you can record this value and perform the calculation yourself or the instrument 
can perform this calculation for you. Repeat step 5 until all samples have been read.  
 
Electrophoresis:  
Genomic DNA fragment sizes were first estimated by agarose gel electrophoresis of 250 
ng DNA using 1 % agarose gels (90 mM Tris–borate, 2 mM EDTA, 1% agarose). 
Samples were stained using SYBR safe (Life Technologies) and ran at ~120 volts for 
about an hour and visualized under GE ImageQuant LAS-3000 camera (GE Healthcare 
Life Sciences, Piscataway, NJ, USA). The Jurkat genomic DNA (Thermo Scientific) was 
used as a positive control for comparison and Lambda DNA-HINDIII Digest (New 
England Biolabs) ladder which is 23,130bp was used for looking and comparing the size 







Samples with visible DNA fragments as large as 23,000 base pairs (bp) were processed 
further by randomly amplified polymorphic DNA PCR (RAPD-PCR) to determine which 
sample is ideal for SNP 6.0 by looking at the amplifiability of each sample that have high 
molecular weight amplicons. Non-specific primers and PCR conditions were used to 
produce multiple amplicons from each sample.  
RAPD-PCR reactions were carried out in a 20 µL volume containing 25 ng DNA and 
using 10µl of GoTaq 2X Green Master Mix (Promega, Madison, WI USA) that contain 
bacterially derived Taq DNA polymerase, reaction buffers at optimal concentrations for 
efficient amplification of DNA templates by PCR, dNTPs, MgCl₂ and Go Taq® Green 
Master Mix contains two dyes (blue and yellow) that allow monitoring of progress during 
electrophoresis. PCR was performed in 0.2mL tubes in a GeneAmp PCR System 9700 
thermocycler (Life Technologies, Carlsbad, CA, USA). 
Primers used for RAPD-PCR were generated by Eurofins MWG Operon Inc (Huntsville, 
AL, USA).  Sequences for the primer pairs and cycling parameters were as follows: 5’-
AATCGGGCTG-3’ and 5’-GAAACGGGTG-3’, denaturation for 94˚C for 2.5 minutes, 
then 45 cycles of amplification (1 minute at 94˚C, 1 minute at 55˚C and 2 minutes at 
72˚C) then final extension for 7 minutes at 72˚C and holding at 4˚C; or 5’- 
TGTGCCCAGTGAAGACTCAG-3’ and 5’- GAGTGAGCGGAGAGGGAACT-3’, 45 
cycles of 94° C denaturation for 1 minute, 35° C amplification for 1 minute, and 72° C 
extension for 2 minute and holding at 4˚C .  PCR products were resolved on 3% TBE 




method will give enough amount of DNA which is around 500bp amplicon length for 
SNP 6.0 protocol, gels were imaged with a GE ImageQuant LAS-3000 camera (GE 
Healthcare Life Sciences, Piscataway, NJ, USA) and visualization was carried out as 
described under Electrophoresis above. 
Microarrays: 
A larger set of 63 skin biopsy specimens (21 benign and 42 melanoma) that includes a 
subset of nine extracted by AFA method and the remaining were extracted by Qiagen 
method were first quantified by Nanodrop, Qubit and RAPD PCR, then processed and 
hybridized to Affymetrix SNP6.0 microarrays. 0.5 µg of genomic DNA was processed 
using the SNP 6.0 protocol and microarrays suggested by Affymetrix (Affymetrix, Santa 
Clara, CA, USA) with some modifications to the standard protocol.  
The original protocol is in Affymetrix Genome-Wide Human SNP Nsp/Sty 6.0 User 
Guide which is as follows; 
Day 1 
1. Sty1 Digestion 
2. Sty 1 ligation 
3. Sty 1 PCR 
Day 2 
1. Nsp 1 digestion 
2. Nsp 1 ligation 





1. PCR QC 2% Agarose Gel 
2. PCR Purification by Iso propanol method 
Day 4 
1. Fragmentation 
2. Fragmentation QC 4% Agarose gel 
3. Labelling 
Day 5 
1. Hybridization of genomic DNA to microarray chips 
Day 6 
1. Fluidics wash of microarray chips 
2. Scan the microarray chips 
Some modifications done by previous student (Sameep Naik) are as follows: 
The input amount of DNA was increased from 250ng per restriction enzyme (Nsp1 and 
Sty1) to 500ng each.  The number of PCR reactions were doubled from the suggested 3 
for Sty1 and 4 for Nsp1 to 6 for Sty1 and 8 for Nsp1.  It is important to note that the 
number of reactions was increased; the number of cycles in each reaction remained the 
same.  The additional PCR reactions were combined as in the standard protocol.  PCR 
cleanup was performed using isopropanol extraction (refer to Affymetrix User Bulletin 2: 




precipitation method, P/N 702968 Rev. 1).  Hybridization, washing, staining and lastly 
scanning of the arrays which are controlled by Affymetrix Genechip Command Console 
(AGCC) software, these steps were followed by the manufacturer’s protocol.  Microarray 
data (CEL, ARR and CHP files) are obtained for every sample when microarray chips 
were scanned using the GeneChip Scanner 3000 7G using AGCC software 
Data Analysis: 
27 benign melanocytic lesions were extracted with each extraction method and these 
three methods were compared and determined statistically by looking into Nanodrop 
concentration (ng/section), 260/280 and 260/230 ratios, Qubit concentration (ng/section), 
RAPD-PCR amplicon lengths, and PCR failure rates using a two-tailed paired student’s t-
test of the mean and standard error. 
The CEL files obtained were processed in Affymetrix Power Tools (APT) provided by 
Affymetrix.  Contrast Quality Control (CQC) which is the primary QC for Genome wide 
Human SNP Array 6.0 was calculated and compared to restriction fragment sizes (for 
Nsp1 and Sty1) to evaluate microarrays to see which PCR products were successfully 
hybridized to the array. It measures the SNP signals and estimate how well they resolve 
into three genotype clusters. A subset of probes were used to measure the differences in 
contrast distributions for both homozygote and heterozygote genotypes.  CQC will assign 
a call rate to each fragment length depending on how successfully they hybridized to the 
array.  Optimally a CQC value ≥ 0.4 [72] is considered a successful hybridization of 





Genotyping Console Software: 
The CEL files of 63 specimens (21 benign and 42 melanoma samples) were added in the 
genotyping console and performed primary intensity quality control (QC) for each 
sample. Intensity QC contains QC metrics, In/Out bounds, #CEL/CHP files, ARR files of 
all samples. First, samples were filtered based on CQC that has a default threshold value 
of greater than or equal to 0.4 which is showed by bounds whether the samples met QC 
value or not. Only samples that passed this QC should be used for genotyping analysis. 
The genotyping console uses algorithm called BIRDSEED V2, it is a SNP genotyping 
algorithm that runs on the Affymetrix SNP 6.0 platform. Birdseed uses a customized 
Expectation-Maximization (EM) algorithm to fit two-dimensional Gaussians to SNP data, 
producing genotypes and confidence scores for every individual at every SNP. Since it is 
a clustering algorithm, it runs on so many samples at the same time (50 or more). The 
batch genotyping results that has sample QC metrics like CQC will be shown in CHP 
summary table. This table generates the batch CHP files. These output format files of 
genotyping console can be used as input files in downstream applications like Partek 
Genomics Suite (PGS) for further analysis. With the help of CHP summary table, SNPs 
list can be generated by filtering the QC call rate with a default threshold of ≥ 90%. The 
call rate is defined as the fraction of called SNPs per sample over the total number of 
SNPs in the dataset. Any samples with SNP call rates below this threshold value are 
omitted from the further analysis since these can cause false positive results. Once SNPs 
list are created, we can export this list to PLINK statistical tool in the standard format 






gPLINK has integration with PLINK which is a statistical tool for whole genome 
association analysis.  gPLINK is a java based program and is a graphical user interface 
tool that uses most of the PLINK command operations. It is free software and can be 
downloaded in this website:  http://pngu.mgh.harvard.edu/purcell/plink/. The output files 
of genotyping console (PED and MAP) are used as input files for gPLINK.  
A PED file is a white-space (space or tab) delimited file where each line 
represents one individual and the first six columns are mandatory and in 
the order ‘Family ID’, ‘Individual ID’, ‘Paternal ID’, ‘Maternal ID’, ‘Sex 
(1 = male, 2 = female, 0 = missing)’and ‘Phenotype (1 = unaffected, 2 = 
affected, 0 = missing)’. The subsequent columns denote genotypes which 
can be any character (e.g. 1,2,3,4 or A, C, G, T). 0 denotes a missing 
genotype. Each SNP must have two alleles (i.e. both alleles are either 
present or absent). The order of SNPs in the PED file is given in the MAP 
file, where each line denotes a single marker and the four white-space 
separated columns are ‘Chromosome (1-22, X, Y or 0 for unplaced)’, 
‘Marker name (typically a “rs_” number)’, ‘Genetic distance in Morgans 
(this can be fixed to 0)’ and ‘Base-pair position (bp units)’[73]. These two 
files are converted to binary PED files (BED) to save space and time. This 
BED file has FAM file that store the pedigree/phenotype information and 
create an extended MAP file (.bim) which contains information about the 




information), plink.fam (first six columns of mydata.ped ), plink.bim 
(extended MAP file: two extra columns = allele names) [74].  
Sample based QC: The first step is to load the Bed files of both benign and melanoma 
samples in gPLINK and then filter them by excluding samples with too much missing 
genotype data which can lead to poor analysis. The default threshold value of 0.1(10%) is 
used which means the samples will be excluded if they have more than 10% missing 
genotype data. 
SNP based QC: After sample QC we apply SNP-based QC for each SNP within each 
sample.  First, SNPs with a rate of missing genotype data ≥ 0.05(5%) are excluded from 
further analysis.  This is to remove any SNP with more than 5% missing genotype data, 
because if they don’t have genotyping data it can lead to false negative, false positive 
results. Next SNPs with a minor allele frequency  0.05 are similarly excluded.  This is a 
frequency at which a least minor allele occurs in a population.  Any SNP with less than 
5% is removed, this filter is applied because SNPs with MAF greater than 5% are said to 
be involved with diseases. Finally, we exclude SNPs with Hardy Weinberg (HW) 
deviations observed from expected p-values of 0.01 or greater. HW equilibrium states 
that allele and genotype frequencies in a population will remain constant from generation 
to generation in the absence of other evolutionary influences. Removing SNPs with 
extreme deviation from equilibrium. All these QC metrics were performed with 






Partek Genomics Suite (PGS): 
 PGS is a software which is a user-interface, easy to use, has built-in workflows for a 
variety of genomic workflows that supports Next generation Sequencing, Microarray data 
and qPCR platforms. We can download the software at their website 
http://www.partek.com/updates , but need license to access it. For studying SNPs, we 
used Association workflow in the PGS. This workflow requires genotyping calls such as 
.CHP files from Affymetrix SNP 6.0 Protocol as input for analysis. We performed 
Sample and SNP based QC for our data and then association analysis for our samples. 
The steps were followed as PGS User Association Workflow guide suggested:  
The Sample QC option will invoke the sample QC spreadsheet, which 
shows one sample per row. 
1.  The rate of missing genotype calls for each sample is given in the 
Sample NC Rate column. The rate is determined by dividing the 
number of no calls (NC) by the total number of genotypes in the 
sample and an unusually high number in this column indicates that the 
overall genotyping quality in the sample is poor. As a rough guide, one 
can tolerate a NC rate of up to 5%.  
2. The Sample Heterozygosity Rate can also be used as a quality 
indicator. As a rule of a thumb, you might want to reconsider the 
samples with the heterozygosity rate which falls out of the interval 
mean ± 3 × standard deviations of all the samples. To calculate the 




please use Stat > Descriptive > Column Statistics… and select mean 
and standard deviation from the list of available Candidate Measures. 
3. After removing the samples which did not pass the sample QC criteria 
you can proceed to the next QC step, Hardy-Weinberg equilibrium, 
which is essentially QA/QC on SNP level. The resulting spreadsheet 
(HWE) features one SNP per row. The difference between the 
observed and expected frequencies of each allele at each locus (or 
SNP) are tested by χ2 test (Chi^
2
 and p-value (Chi^
2
)).  
4. Frequencies of both alleles are provided in the columns A Freq and B 
Freq, while the minor allele frequency (MAF) corresponds to the one 
with lower frequency. The remaining three columns contain the no-call 
frequency (NC Freq), heterozygous frequency (Het Freq), and 
homozygous frequency (Homoz Freq) at the given locus. 
5.  Depending on the annotation provided by the array vendor, it may be 
possible to annotate the SNPs with exact base calls at each locus. 
Please right-click on a column header and select Insert Annotation. In 
the Add Rows/Columns to Spreadsheet dialog, please tick mark the 
Allele A and Allele B boxes. Two new columns will be added to the 
HWE spreadsheet and will contain the genotype of each allele. 
6. At this stage, the following two filters may be considered: 1. A SNP 
no-call rate should be less than 5%. 2. Minor allele frequency of a SNP 




7.  After that, have removed the SNPs that are not in Hardy Weinberg 
equilibrium. For that purpose, a multiple testing correction should be 
applied to the exact p-value: the cut-off p-value after the correction 
equals 0.05 / (number of SNPs left after 1st and 2nd filter) (in the other 
words, Bonferroni’s correction). The filtering can be performed by the 
interactive filter (the icon), to first filter in the SNPs with the NC 
frequency less than 0.05, and then to filter in the SNPs with MAF 
greater than 0.05. Please note that the effects of the interactive filter 
are additive. 
8. However, in order to proceed to the next step of the workflow, the 
changes (i.e. filtering in of SNPs which met the chosen QA/QC 
criteria) have to be applied to the parent spreadsheet; the same SNPs 
need to be filtered in. 
9.  To do that please select the parent spreadsheet (in this example this is 
the one with 17 samples on rows) and then choose Filter > Filter 
Columns > Filter Columns Based on a List… In the Filter Columns on 
Spreadsheet dialog, please set the Filter based on spreadsheet to the 
spreadsheet containing the final SNPs and set the Key column to SNP. 
Association Analysis: 
After filtering samples and SNPs, now we perform association analysis 
using chi-square test. The steps are as follows: 
10. To set the phenotype (categorical variable) this will be tested for 




frequencies as specified by the model (please see the discussion 
below) will be compared between the categories.  
11. By setting the Column variable to Tissue, in this example, one will test 
the association of the SNPs with cancer.  
12. The model section allows for specification of the statistical model.  
Allele: frequencies of alleles (A vs. B) are compared across the 
categories of the selected variable (i.e. phenotype). 
13. Significant p-value indicates that the allele/genotype frequencies are 
different between the categories of the selected variable, i.e. that an 
association exists between the genotype and the phenotype. 
14.  In the present example χ2 statistic was used to assess the difference in 
allele frequencies (allele model) between the normal and cancer 
samples. The resulting spreadsheet (Chi-square) shows one SNP per 
row.  
15. PGS provides the value the associated p-value (chisq p-value) for each 
SNP. 
This p-value along with the genes associated with the filtered SNPs are saved as tab 
limited text and is exported to IPA. 
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Ingenuity Pathway Analysis (IPA) is a web-based functional analysis tool for 
comprehensive genomic data. Quickly gain knowledge on the genes by browsing 
categorized and curated publication. To download this software go to their website 
http://www.ingenuity.com/products/ipa, which is available for 7 day free trail and have to 
sign up before you want to download. An email will be sent to your email address which 
has the link to download the IPA software. Download and install IPA. First import the 
genes list from PGS. 
1.  When you hit “run the core analyses” it will show up all the diseases that the genes 
associated with them. 
2. Click on the “cancer” disease and then once a new tab opens where it shows all the 
cancers, click on the “melanoma” cancer. 
3. List of genes and their associated SNPs will show up based on the literature and 
databases integrated with IPA. 
 




III. RESULTS AND DISCUSSION 
 
A total of 27 dermal nevi specimens, preserved in formalin and embedded with paraffin 
(FFPE), were selected from DLCS. These FFPE block tissues can be stored for a very 
long time and their accreditation requirements can be fulfilled easily, because of this we 
were interested in FFPE tissue blocks. The College of American Pathologists (CAP) 
Commission on Laboratory Accreditation at the present time needs FFPE blocks to be 
retained for 10 years [75, 76] and also the surgical pathology records.  These FFPE tissue 
blocks can be used for research purposes as long as 1) HIPAA requirements for patient 
privacy are followed 2) the diagnostic laboratory keeps enough tissue for diagnostic 
purposes, 3) the diagnostic laboratory has facilities to return any FFPE material 
remaining after use in research and 4) the demands of applicable institutional review 
boards (IRB), state and local laws are adhered to. Additionally, CAP currently suggests 
retaining the archived materials beyond 10 years if possible mainly because of the 
demand for these specimens for several research areas including cancer research as 
biomarkers are developing. The clinical data of these specimens, such as patient age, 
diagnosis and the age of these blocks and their storage at the room temperature for an 
average period of 8.67 years and average age was 38 years are shown in Table 1.There 
was enough material found on these specimens for the three extraction methods. For 
DNA extraction, the sections were cut sufficiently from each sample according to each 




hematoxylin and eosin (H&E) and observed under microscope (Figure 1) and used for 
further analysis only if the slides from beginning to the end that were cut have at least 
50% of tumors present in each section of sample.   Sometimes when we cut we exhaust 





Examining the H&E sections on either side of our analyzed sections tells us whether the 
samples we take for further analysis contain sufficient tumor cells, and allows us to 







(years) Clinical notes 
1 30 F 8 Biopsy, nose, left side dermal nevus 
2 25 M 8 Biopsy, scalp, right post dermal nevus 
3 16 M 8 Biopsy, abdomen left dermal nevus 
4 35 F 8 Biopsy, back, left center dermal nevus 
5 38 M 8 Biopsy, scalp dermal nevus 




6 21 M 8 Biopsy, back right middle dermal nevus 
7 26 M 8 Biopsy, abdomen dermal nevus 
8 32 F 8 Biopsy, cheek, right dermal nevus 
9 31 M 8 Biopsy, axilla, right dermal nevus 
10 69 F 8 Biopsy, back, right upper dermal nevus 
11 40 F 8 
Biopsy, axillary area. Anterior nevus lipomatosus 
superficialis 
12 44 F 8 Biopsy, calf, left post dermal nevus 
13 22 F 8 Biopsy, chest, left lateral neurotized dermal nevus 
14 56 M 8 Biopsy, cheek, left intradermal melanocytic nevus 
15 47 F 8 Biopsy, axilla, left dermal nevus 
16 35 F 8 Biopsy, chest dermal nevus 
17 29 F 8 Biopsy, back, midline lower neurotized dermal nevus 
18 34 F 8 Biopsy, deltoid left ant dermal nevus 
19 44 F 8 Biopsy, lip, left upper dermal nevus 
20 75 F 8 Biopsy, knee, left medial dermal nevus 
21 36 M 8 Biopsy, axilla right dermal nevus 
22 60 F 11 Biopsy, back dermal nevus 
23 16 F 11 Biopsy, back, left upper dermal nevus 
24 41 F 11 Biopsy, forehead, right neurotized dermal nevus 
25 16 F 11 Biopsy, back, inferior lower dermal nevus 
26 35 M 11 Excision, malar, left dermal nevus 







In spite of the accessibility of archived specimens, the procedure of fixation leads to the 
difficulty of using the nucleic acids from these FFPE tissue blocks [77]. So as to 
overcome these hurdles, it is essential to use effective extraction methods for the nucleic 
acids. For this, we extracted DNA and compared the three methods from the same 27 









 ratios, and the purity of DNA.  This can be analyzed by looking into the 




“amplifiability” of each DNA sample by performing RAPD-PCR to see if the 
contaminants such as xylene, ethanol and salts are inhibiting the PCR reaction. We found 
that the quality and quantity of extracted DNA can remarkably affect the downstream 
processes. 
Using the three extraction methods phenol-chloroform isoamyl alcohol, Qiagen-
commercial kit and AFA (Adaptive Focused Acoustic), 27 samples were extracted. So 
many literature suggested different deparaffinization timings and protein digestion times 
[59, 78-81]. Increasing protein digestion time from overnight to 72 hours can increase the 
DNA yield according to some studies[77, 79] ,so in the Qiagen QIAamp DNA FFPE 
Tissue Kit method, the samples were digested with proteinase K for 72 hours instead of 
overnight digestion in order to get better yield of the DNA. In phenol chloroform isoamyl 
alcohol method, protein digestion was performed for 72 hours to increase the yield. After 
protein digestion, the samples were incubated at 94˚C for about 40 minutes to reverse 
crosslinks.  The higher the temperature and more incubation time will be better for 
reversible cross-linking[82],but if the DNA is not cross-linked can cause fragmentation, 
affect downstream applications [83-85] and also to melt any paraffin that is left in the 
sample [86]. In order to precipitate the DNA in the samples, they were either kept at -
80˚C for about 1 hour or can keep at -20˚C for about an overnight[59] ,depending on 
whether you want to proceed the extraction method immediately or later. The glycogen 
used in this method is to increase the size of the pellets in our samples, but it is avoided 
since our samples had enough pellet size. Xylene is used in both phenol chloroform and 
column based extraction methods to remove paraffin. Even though xylene can remove 




downstream processes like PCR[88]. So it is better to avoid xylene in any extraction 
process. On the other hand, the AFA does not need xylene or any other organic solvents 
to remove paraffin. But the deparaffinization takes place in the AFA machine by creating 
focused bursts of ultra-sonic acoustic energy; this causes hydrodynamic shear stress, 
emulsification of paraffin and tissue rehydration at the same time.  Because of no xylene 
and automatic removal of paraffin by acoustic energy in this method, the amplicon length 
in the RAPD PCR (Figure 2 and Table 2) is increased for the AFA samples when 
compared to other two methods. 





264.3  35.4 134.6  18.1 
DNA (ng)/section 
(Nanodrop)  
702.1 200.2  716   116.1  453.8  53.9 
A260/A280 1.94   0.02 2.04  0.03 1.90  0.02 
A260/A230 1.71   0.18 1.71  0.12 1.75  0.43 
Max. amplicon (bp) 346.7   24.1 347.4  21.4 401.9  10.2 




Table 2: Summary of the three Methods Comparison for 27 samples 










The deparaffinization time in AFA method was increased from 300 sec to 500 sec 
because initially the paraffin was not removed properly with 300 sec time and so to 
Figure 2: RAPD PCR comparison for the three methods. All the four samples (1, 2, 3, and 4) 
were compared with negative and positive control (PC; Jurkat DNA) and these same 




improve this step we increased the time. The main factors of these three extraction 
methods are compared and given in Table 3. 
Factors  AFA Qiagen  PCI 
Number of sections 
(10µm thickness) 
~10 ~24 ~24 
Protein Digestion 
time 
~2 hours ~ 72 hours ~ 72 hours 







After extracting the genomic DNA of 27 samples with three methods, the best way to 
qualify the genomic DNA is to look at the quantification and assessment of dsDNA [89, 
90] for downstream analysis. This qualification can be done by checking the 
contaminants (ethanol, phenol) in the samples with Nanodrop by looking into 260/280, 
260/230   ratios. Then look into Qubit concentrations for more accurate concentration of 
DNA. This is because the dye in the Qubit assay only binds to the double stranded DNA 
whereas Nanodrop shows high concentration, since it measures absorption at different 
wavelengths like 230nm, 260nm. For the nucleic acids the absorption takes at 260nm, 
and so it measures absorption to oligos, single nucleotides, ssRNA rather than just to 
dsDNA. The 260/280, 260/230, Nanodrop and Qubit concentrations are shown in Table 
2. The DNA yield per section for Qubit was also shown in Table 2, Figure 3 and for 
Nanodrop is shown in Table 2, Figure 4. This is calculated based on the elution volume 
and the number of sections used per sample.  







The column samples showed better yield per section (p<10
-4
). Even though the 
column sample showed better yield per section, it is also important to consider the 
sample purity, reasonable PCR amplicon sizes and less PCR failure rates for using 
these samples in SNP genotyping, FISH, comparative genomic hybridization and 
other techniques. Since DNA purity is important to consider for downstream 
applications, we looked the 260/280 and 260/230 ratios. The 260/280 ratio (Table 
2, Figure 4) is the first measure to look for purity of the nucleic acid and it should 
have ~1.8 value, all the three methods slightly have around 1.8 .260/230 (Table 2, 
Figure 5) is the second measure for the purity of the nucleic acid and anything 
around 2 shows the nucleic acids are pure. All three methods have A260/A230 










 Figure 5: A260/230 ratios comparisons of three methods 




To see the size range of the genomic DNA they were separated by 1% agarose gel 
electrophoresis.  For comparison we took the same 4 samples that are extracted with three 
methods (Figure 6).  
 
 
Total amount of the genomic DNA range in the gel is almost similar which shows that the 
three methods worked the same way. Since RAPD-PCR is one of the good ways to 
quantify our samples, we now looked at the amplicon size of the 4 samples in Figure and 
for 27 samples in Table 2. Of all the AFA had showed higher amplicon length compared 
to other methods(Figure 7, p 0.04), this could be because of not using xylene that can 
interfere with the DNA and can lead to poor PCR analysis and also the PCR failure rates 
was low (3.70%) for AFA compared to the other two methods ( Table 2). Eliminating the 
contaminants that are carried over during purification process is measured by the rate of 
“PCR failure” (Table 2).   







When RAPD-PCR showed amplicons size of less than 300 bp in length, we did not use 
those samples as it anticipates poor performance in the downstream PCR [91].  The 
failure rates were around 25% by phenol-chloroform and around 22% by columns. On the 
other hand, only one of 27 samples (3.7%) failed by AFA. 
Aim 2: After extracting good quality of DNA with AFA method from benign FFPE 
specimens, we used a Qubit fluorometer to determine DNA concentration. Since the 
concentrations were less in Qubit we used a speed vac to concentrate the DNA.  First, by 
adding distilled water to the each sample to bring up the concentration to as close to 
500ng/µl for each Sty and Nsp reactions in digestion and ligation process and one of the 
advantage of using speed vac is that it will evaporate any leftover solvents like ethanol to 
avoid carryover contamination.  Then the samples were processed and hybridized to the 
SNP 6.0 array comparative genomic hybridization (aCGH) microarrays. Some studies 




have shown that aCGH works well with FFPE specimens [47, 92] for analyzing the 
tumor tissues [93-95] [96]. Also aCGH is helpful in distinguishing the malignant 
melanoma from benign cases [45, 97-99] that are ambiguous since distinguishing them 
can be difficult for the pathologists. Many factors like the age of FFPE tissue block, 
storage, and also the quality of the DNA obtained from the FFPE tissues can affect the 
downstream applications like Array CGH.   In the SNP 6.0 protocol, we performed QC 
steps at two stages to see how qualitatively our AFA samples look. One after we perform 
PCR for these AFA samples and this is shown in Figure 8 Affymetrix suggests to have 




In the 4% agarose gel above the Sty and Nsp samples were in between the range 
suggested by Affymetrix. So we checked the concentrations and purity of the AFA 
Figure 8: Post PCR gel image in SNP 6.0 Protocol, 5 Sty and Nsp samples were 




samples using Nanodrop .The DNA quantity was sufficient enough for all samples which 
is around 3500 bp that is suggested by Affymetrix SNP 6.0 protocol and the purity of the 
samples were also within range (Table 4). 






B282 5241.4 1.59 1.87 
B283 5380.3 1.47 1.73 
B285 3258.1 1.92 2.23 
B286 4688.6 1.79 2.09 
B287 3962.5 1.87 2.17 
 
 
After the first QC, we performed the fragmentation step using the PCR to fragment the 
PCR products so that these small fragments can successfully hybridize to the arrays.  
Affymetrix SNP 6.0 protocol says that the fragments should be less than 180 bp length to 
successfully hybridize to the arrays. The samples were run on 4% Agarose gel to assess 
the fragment size of the samples (Figure 9). All of the samples were fragmented in 
between 100 and 200 bp. 
Table 4: PCR products of AFA samples showing their Nanodrop 







(We judged that the quantity of the DNA within the 100-200 bp range was probably 
sufficient for hybridization, but this could have been further fragmented by repeating 
fragmentation step for about 30 minutes or could have done this step three times each 
reaction for 10 minutes rather than one reaction for 30 minutes to increase the DNase I 
activity [63]. Rather than over-fragment the DNA, it was utilized as it was, and the end 
results validated this decision.)  The fragmented samples were hybridized onto the 
microarrays, and these microarrays were stained and washed if any fragments that were 
not hybridized will be washed out. The microarrays were scanned using GeneChip 
Scanner by Affymetrix and CEL files were obtained. 
                                    
Figure 9: Fragmentation of PCR products on 4% Agarose Gel 




  Microarray Analysis: 9 AFA samples have been able to pass the QC steps in the SNP 
6.0 protocol (PCR and fragmentation steps) i.e.; they have showed enough amplicon 
length, concentrations and fragmented with ≤ 200bp of length. We used these AFA 
samples along with the column samples to do next steps. Once CEL files are obtained we 
further proceeded with microarray analysis by comparing 63 specimens of both columns 
(54) and AFA (9) samples. The details of these 63 specimens are given in Table 5. 





Sex Location Clark's 
level 
Type 
1 M07 77 2008 Male Right Arm IV SUPERFICIAL SPREADING 
TYPE 
2 T10 - 2005 Male - - MALIGNANT MELANOMA 
3 T12 80 2005 Male Forehead IV DESMOPLASTIC TYPE 
4 T15 75 2005 Female Upper Back IV/V SUPERFICIAL SPREADING 
TYPE 
5 T17 - 2006 Male - - MALIGNANT MELANOMA 
6 M18 40 2007 Male Back IV MALIGNANT MELANOMA 
7 T19 60 2007 Female Left Leg IV NODULAR SPITZOID TYPE 
8 T20 - 2007 Female Elbow IV SUPERFICIAL SPREADING 
TYPE 
9 T23 81 2008 Male Left 
Auricular 
IV SUPERFICIAL SPREADING 
TYPE 
10 M27 93 2001 Male Right Groin IV NODULAR MALIGNANT 
MELANOMA 
11 M28 60 2007 Female Left Leg IV NODULAR SPITZOID TYPE 
12 M30 - 2011 Male - - MALIGNANT MELANOMA 
13 M31 63 2008 Female Right 
Forearm 
IV SUPERFICIAL SPREADING 
TYPE 
14 M33 76 2008 Female Right Cheek IV SUPERFICIAL SPREADING 
TYPE 
15 M50 57 2010 Male Left Arm IV SUPERFICIAL SPREADING 
TYPE 
16 M54 45 2012 Female Left Back IV ULCERATED NODULAR 
MALIGNANT MELANOMA 
17 M56 60 2012 Male Left Shin IV SPITZOID TYPE 
18 M58 66 2011 Male Right Cheek  POORLY-DIFFERENTIATED 
CARCINOMA!!! 
19 M59 77 2011 Male Right Elbow IV INVASIVE MALIGNANT 
MELANOMA 






21 M74 69 2010 Male Left Temple IV SUPERFICIAL SPREADING 
TYPE 
22 M75 74 2010 Male Left Neck IV SUPERFICIAL SPREADING 
TYPE 
23 M76 67 2010 Female Right Back IV Malignant Melanoma with 
vertical Growth 
24 M77 53 2010 Male Right Arm IV NODULAR MALIGNANT 
MELANOMA 
25 M84 - - Female - - MALIGNANT MELANOMA 
26 M86 54 2009 Female Anterior 
Thigh 
IV SUPERFICIAL SPREADING 
TYPE 
27 M98 72 2005 Male Right 
Shoulder 
III SUPERFICIAL SPREADING 
TYPE 
28 M107 80 2005 Male Forehead IV DESMOPLASTIC TYPE 
29 M111 48 2005 Female Right 
Forearm 
V NODULAR VARIANT 
30 M113 40 2007 Male Back IV Malignant melanoma 
31 M116 74 2007 Female Right Arm II SUPERFICIAL SPREADING 
TYPE 
32 M130 63 2001 Male Back IV SUPERFICIAL SPREADING 
TYPE 
33 M131 45 2001 Female Left Arm III SUPERFICIAL SPREADING 
TYPE 
34 M132 75 2001 Male Right Chest III-IV DESMOPLASTIC TYPE 
35 M136 40 2001 Female Upper Back III-IV NODULAR TYPE 
36 M137 85 2001 Female Right Cheek IV/V Malignant melanoma 
37 M139 87 2001 Male Right Cheek V CONSISTENT WITH THE 
LENTIGO MALIGNA 
MELANOMA SUBTYPE 
38 M147 90 2002 Male Left Back IV SUPERFICIAL SPREADING 
TYPE 
39 M148 55 2002 Female Middle Back II/III SUPERFICIAL SPREADING 
TYPE 
40 M173 28 2008 Female Left 
Shoulder 
III INVASIVE SPITZOID 
MALIGNANT MELANOMA 
41 M174 42 2008 Male Right 
Pretibial 
III SUPERFICIAL SPREADING 
TYPE 
42 M191 75 2001 Male Left Back IV MELANOMA WITH 
REGRESSION 
43 NT06 34 2010 Male Right Arm - DERMAL NEVUS 
44 NT07 44 2010 Female Right 
Buttock 
- DERMAL NEVUS 
45 NT12 - - Male - - DERMAL NEVUS 
46 B15 19 2010 Female Left Back - DERMAL NEVUS 
47 B27 39 2011 Male Left Neck - DERMAL NEVUS 
48 B29 35 2011 Male Left Flank - DERMAL NEVUS 
49 B30 34 2011 Female Right Neck - DERMAL NEVUS 
50 B31 44 2011 Male Right Groin - DERMAL NEVUS 
51 B47 27 2011 Female Right Back - DERMAL NEVUS 





53 B52 48 2011 Female Left Neck - DERMAL NEVUS 
54 B53_3 75 2011 Female Left 
Shoulder 
- DERMAL NEVUS 
55 B254 34 2007 Female Left Deltoid - DERMAL NEVUS 
56 B267 33 2013 Female Right Back - DERMAL NEVUS 
57 B272 38 2013 Female - - DERMAL NEVUS 
58 B279 52 2013 Female Right Back - DERMAL NEVUS 
59 B282 41 2013 Female Right Neck - DERMAL NEVUS 
60 B283 14 2013 Female Right 
Shoulder 
- DERMAL NEVUS 
61 B285 16 2013 Female - - DERMAL NEVUS 
62 B286 21 2013 Male Right Back - DERMAL NEVUS 
63 B287 60 2013 Female Right Neck - DERMAL NEVUS 
 
 
 However, we did not use phenol samples even though they have good amplicon sizes in 
the RAPD-PCR, they did not have sufficient amplicon length in the PCR, also the 
concentrations were lower than 3000 ng\µl in the SNP 6.0 protocol. Using these CEL 
files of these 63 specimens we did fragment length analysis by using Affymetrix Power 
Tools (APT). APT analyzes the microarrays and assigns a call rate to every probe 
depending on how successfully they hybridized to the microarray. Probes are sorted by 
the size of the restriction fragment on which they occur.  If any piece of region within the 
restriction sites is missing then this region will also be missing in the samples that are 
hybridized to the arrays. Any fragment of genomic DNA that is hybridized successfully 
should have at least a contrast QC of 0.4. The Contrast QC captures the ability of an 
experiment to resolve SNP signals into three genotype clusters. Here APT measures 
contrast QC and we compared both AFA and column restriction fragment sizes of Nsp1 
and Sty1 (Figure 10). Any fragment size showing below 0.4 threshold of CQC shows that 
the samples have poor quality. AFA showed largest fragment size of 400 bp in Sty and 




500 bp in Nsp compared to the column samples. This APT analysis tells about the quality 
of the DNA, the more range of fragments present per sample the better the data it will 
have and can increase the yield of downstream analysis. Even though AFA showed better 
fragment sizes, they still have missing fragments above 500 bp.  This could be because of 
the starting material (FFPE tissue) quality or samples could have not hybridized properly 
to the arrays. 
 
   
 






 All 63 specimens ( including benign and melanocytic nevi) were hybridized on to the 
Affymetrix SNP 6.0 microarrays were analyzed in Genotyping Console (GTC) by 
Affymetrix, gPLINK, and Partek Genomics Suite (PGS) to perform association analysis. 
The 63 CEL files that were obtained after the scanning of microarray chips were opened 
in Genotyping Console for genotyping analysis. Before performing genotyping, we 
checked the QC of the samples. The overall quality of samples were tested with contrast 
QC (CQC) algorithm with a threshold value of ≥0.4.We use this because it is the default 
CQC value established by Affymetrix for Genome-Wide Human SNP 6.0 array samples.  
The Contrast QC captures the ability of an experiment to resolve SNP signals into three 
genotype clusters. It uses a static set of 10,000 randomly chosen SNP 6.0 SNPs (Figure 
11 taken from GTC 4.1 user manual); measuring the difference between peaks in contrast 
distribution produced by homozygote genotypes, and the valleys they share with the 
heterozygote peak, and takes the smaller of the two values. In poor quality experiments 
the homozygote peaks are not well-resolved from the heterozygote peak and the 








Samples passing the contrast QC threshold should show “In bounds” for 
each sample but all of our samples were “out of bounds” which means 
they have <0.4 value. Not every SNP is generated by both the StyI and 
NspI enzymes but some will have the SNPs with just one enzyme set. This 
issue can be solved by contrast QC. So this Contrast QC values are 
calculated for contrast distributions produced by a static set of 20K 
randomly chosen SNPs on NspI fragments and a static set of 20K 
randomly chosen SNPs on StyI fragments. These are called Contrast QC 
(NspI) and Contrast QC (StyI), respectively. If the absolute difference 
between these two values is greater than two, this is evidence that that a 
sample may have worked properly with one enzyme set, but not with the 
Figure 11:   Distribution of Contrast Values. The X axis is the Contrast Value about which 
a bin of size 0.02 is centered. The Y axis is the % of SNPs (10000 random autosomal GW 
6 SNPs) whose Contrast values fall within the bin. Contrast = sinh[K*(A-
B)/(A+B)]/sinh(K)], K=2, A and B are the summary values for probes covering the A and B 




other, and the Contrast QC value is adjusted to zero to reflect this 
problem. 
 Even though if the samples are “out of bounds” or did not pass the threshold value we 
can still consider the samples for further analysis (genotyping) if we keep in mind the 
limitations of the study.  
Genotyping analysis identifies genomics variations (SNPs) in the genomes of different 
individuals. For analyzing SNPs in our samples we performed genotyping analysis. The 
genotyping results display CHP summary statistics where it shows call rate of all 
samples. The call rate of a sample is defined as the fraction of the number of SNPs called 
out of all SNPs on the array. Our samples had an average call rate of 61.73%. The higher 
the call rate the better we can avoid the false positive/false negatives in the analysis. A 
good call rate can be greater than 90%.  This low call rate could be because of some of 
the samples did not pass the intensity QC which tells that some samples are missing the 
expected SNPs on the probes.  The genotyping calls of 909,622 SNPs for every sample 
were determined using the Birdseed V2 genotype calling algorithm, which is in the 
Affymetrix GTC software. The samples were assigned genotypes and then SNPs were 
removed when they have low call rate of ≤90%, any SNP above or equal to 90% means 
they are good enough for the analysis.  The low call rate in our experiment indicates that 
more than 10% of the SNPs for our samples have missing genotype data. This can cause 
serious analysis complications downstream. With the help of CHP files, a SNPs list was 
created for SNPs with call rates ≥90% in our samples. The number of SNPs before and 
after filtering is summarized in Table 5. The flow chart shows the steps in the genotyping 




gPLINK in the format of PED and MAP files. The PED file has information about the 
sample like Family ID, Individual ID, phenotype and gender whereas MAP file contains 
information about marker ID (rs...), chromosome number and base pair position. The 
quality control (QC) measures are an important step for studying genotype data of 





63 CEL files  
Sample QC≥0.4 
(using CQC Algorithm) 
Sample 
call rate≥90% 




Filtered SNPs list 
Exported to gPLINK in 
PED and MAP file formats 
Exported to Partek 
Genomics Suite (PGS) 
Figure 12: Flow chart showing the QC steps for both 
Samples and SNPs in GTC  
Genotyping Analysis 






1. The PED and MAP files from GTC were first converted to BED files to bring the 
information in these two format files together and save space. This BED file is first 
filtered with recommended QC steps [73, 100]. The recommended SNP QC steps are 
minor allele frequency, missingness rate, and Hardy Weinberg equilibrium. First, the 
samples were filtered using missingness rate per individual (MIND) with a threshold of 
0.1this is a good indicator of marker quality.  This will remove the samples that have 
more than 10% missing genotype data since more missing genotyping data leads to false 
positive or false negative results [100]. But all of our samples have less than 10% missing 
genotype data. Then we applied SNP based QC for every SNP in every individual. The 
first SNP based QC step for SNPs is   minor allele frequency (MAF).  This refers to 
the frequency at which the least/ less abundant allele occurs in a given population. Any 
SNP with a 5% or less minor allele frequency are removed. . We use MAF to remove 
SNPs because the statistical power is very low to detect association for rare SNPs 
(usually < 1% frequency), so it is better to remove these rare SNPs to avoid burden for 
the analysis using the power of statistical tools [100]  Next SNP based QC is the missing 
rate per SNP (GENO) with a threshold of 0.05 is used to filter out some more SNPs.  If 
they have more than 5% missing genotype data that can increase the rate of false results. 
A summary is provided in the Table 6 to show the total number of samples and SNPs 
excluded and included after QC in the analysis.  
2. SNPs were again filtered based on their Hardy Weinberg (HW) equilibrium. HW is a 









Samples in study 
 
SNPs in study 
Before QC After QC Before QC After QC 
GTC 63 63 818245 319777 
gPLINK 63 63 316244 107385 
 PGS                 63 63 909622 107909 
                   
 
Any SNPs that are deviated from this equilibrium are removed.  any deviation from HWE 
threshold shows that genotyping error happened and/or the controls having association 
with the diseases [73].Explained with details about the HWE in PGS section. 
A difficulty with gPLINK is any sample with “unknown gender” or “wrong gender” will 
be removed from analysis since gPLINK considers this warning as an error. There are 
some unknown genders in our samples. Also not every command in PLINK is available 
in gPLINK like “gender check” to avoid the problem discussed above. PLINK/gPLINK 
does not have proper contact in case if we want to ask any questions or have any 
concerns. So as a new starter, it will take time to understand and interpret the results.  
Table 6: This summarizes the number of SNPs and Samples filtered out after QC 




Partek Genomics Suite (PGS): 
In contrast to gPLINK, PGS does not remove any samples with unknown gender since it 
takes the CHP summary files from GTC as the input, so we used PGS for further 
analysis. Partek Genomics Suite is statistical analysis software that is user friendly, fast, 
memory efficient, can work on large sets of data. It has several built-in workflows for 
genomic data analysis like microarray and next generation sequencing workflows which 
are easy to use. For our microarray data (CHP files) we used Microarray Association 
workflow. Here we did sample and SNP-based QC steps. 63 Samples were filtered using 
the no call rate (NC) for sample which means the rate of missing genotype calls for every 
sample; it is a good way of assessing the sample quality. It has a default threshold of 
≤5%, any sample with greater than 5% missing genotype data are removed since it can 
cause false-positive and false-negative results and sample heterozygosity rate which is 
the proportion of heterozygous genotypes for an individual [73] is an indicator of sample 
DNA quality. the threshold for this rate is 0.908412 (max)–0.08313(min). The 
heterozygosity rate of all samples should fall in the interval of mean±3* standard 
deviation. Any sample out of this range is removed which means the samples have less 
DNA quality [73] After this, we performed SNP based QC for every SNP in each sample. 
Hardy Weinberg equilibrium, a SNP based QC step is a model which states that the 
genotype and allele frequencies of a given population will be constant from generation to 
next in the absence of other evolutionary influences. any deviation from HWE threshold 
shows that genotyping error happened and/or the controls having association with the 
diseases [73]. Usually HWE is tested first for controls because they will have similar 




value with a default threshold of > 0.05. p-value is used to test statistical hypothesis of 
the observed sample results. Any SNP (in controls) with the observed p-value is less than 
the expected p-value(0.05) is deviated from the HWE and thus excluded from the further 
analysis [73]. This p-value is compared against the allele/genotype frequencies of 
controls. Before performing the HWE QC step, we have to filter SNPs with No call NC 
frequency for SNP which also gives a good assessment for every marker quality, is the 
rate of missing genotype calls for every SNP; any SNP will be removed if it has greater 
than 0.05 missing genotype data to avoid spurious results. Then the next QC step is minor 
allele frequency (MAF). This refers to the frequency at which the least/ less abundant 
allele occurs in a given population.   The default threshold is greater than or equal to 0.05 
which means any SNP with less than 0.05 MAF value is removed. We use MAF to 
remove SNPs because the statistical power is very low to detect association for rare SNPs 
(usually < 1% frequency), so it is better to remove these rare SNPs to avoid burden for 
the analysis using the power of statistical tools [100]  Once SNPs are removed with the 
NC frequency, MAF and p-value of HWE, then we used an allelic chi-square test, this chi 
square test is used to determine if there is any significant differences between observed 
and expected allelic frequencies between cases melanomas) and controls (benign).  In this 
test, the SNPs were filtered again based on chi-square p-value using a cutoff p-value of 
0.05. This p-value here is compared against cases and controls. Any SNP that has a p-
value greater than 0.05 was excluded from the analysis. Significant p-value (≤ 0.05) 
shows that the allele frequencies are different between the cases and controls, which 
mean there is an association exists between the allele or marker and the increased risk of 




controls to our cases. This test is just to see whether the samples have any poor 
genotyping data, or have any inbreeding which can lead to biased comparison with other 
population (cases). The parameters and thresholds are recommended by the PGS and 
shown in Table 7. After these steps, we have the filtered SNPs list along with their 
associated genes and chi square p-value. All the steps after using GTC are given in Figure 











Sample QC & Thresholds SNPs QC & Thresholds 
gPLINK Missingness rate per 
individual (MIND)≤ 10% 
Missingness rate per SNP≤5% 
Minor allele frequency(MAF)≥5% 
Hardy Weinberg Equilibrium 
(HWE)<5% 
PGS No call Frequency≤ 
5%Sample 




No call frequency≤ 5% 
Minor Allele Frequency(MAF)≥ 5% 
Chi-square p-value≤5% 
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expected allele frequencies in controls 
 
63 Samples 
 107909 Filtered SNPs and 
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literature in IPA 
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expected allele frequencies of SNPs in cases vs controls)  
Only Genes with lowest chi-square 
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Figure 13: Flowchart showing the steps in getting the filtered SNPs using PGS and 




Ingenuity Pathway Analysis is a web based functional analysis tool for comprehensive 
genomic data. We are interested in IPA because we want to explore the significance of 
our findings. The genes list is being exported to Ingenuity Pathway Analysis (IPA) to 
look whether the genes are known to be involved in cancer (especially melanoma) by 
taking the genes with SNPs having the lowest associated p-values. By making the chi-
square p-value even stricter - , filtered out the SNPs within the range of ≥1.08E-22 & 
≤5.30E-26 and we limited the analysis to 7,389 genes.    The SNPs and genes list from chi-
square allelic test are shown to be involved in the melanoma in the IPA based on several 
databases like COSMIC, OMIM, Gene Ontology. These genes along with the SNPs 
shown in IPA were compared back to the corresponding SNPs list we got from the chi-
square test in the PGS to validate our findings. We found some genes and their associated 
SNPs in the melanoma that are published in the literature are also present in our samples. 
Some SNPs are found in both melanoma and benign samples and some are just in 
melanoma. These SNPs in benign may predispose the benign to malignant melanoma 
according to a literature [54].  These are listed in the Table 8.  
SNP ID GENES References 
rs1267649 (B&M)  BRAF Meyer, P., C. Sergi, and C. Garbe, 
Polymorphisms of the BRAF gene predispose 
males to malignant melanoma 
rs401681(M) CLPTM1L Stefanaki, I., et al., Replication and 
predictive value of SNPs associated with 
melanoma and pigmentation traits in a 
Southern European case-control study 
rs4845618(B&M) IL6R Gu, F., et al., Interleukin and interleukin 
receptor gene polymorphisms and 




rs2736100(M) TERT Iles, M.M., et al., The effect on melanoma 
risk of genes previously associated with 
telomere length 
rs9420907(B&M) OBFC1 Iles, M.M., et al., The effect on melanoma 
risk of genes previously associated with 
telomere length 
rs10757257(B&M) MTAP Kvaskoff, M., et al., Polymorphisms in 
nevus-associated genes MTAP, PLA2G6, and 
IRF4 and the risk of invasive cutaneous 
melanoma 
rs1015362(B&M) ASIP Maccioni, L., et al., Variants at chromosome 
20 (ASIP locus) and melanoma risk. Int J 
Cancer 
rs2284063(B&M) PLA2G6 Kvaskoff, M., et al., Polymorphisms in 
nevus-associated genes MTAP, PLA2G6, and 





Some SNPs are found both in melanoma and benign (B&M) and some just found in 
melanoma (M). CLPTM1L rs401681 are originally found to be in lung cancer as well as 
melanoma [101] and TERT rs2736100 [102] both found in melanoma cases only whereas 
BRAF rs1267649 [103] , IL6R rs4845618 [104], ASIP rs1015362 [105] , OBFC1 
rs9420907 [102]. MTAP rs10757257 [54] and PLA2G6 rs2284063 [54] are found in both 
benign nevi and melanoma.  
CLPTM1L rs401681 
CLPTM1L gene is associated with the cisplatin-induced apoptosis and it lies in the 
cancer susceptibility locus on chromosome 5p 15.33, this is usually over expressed in the 
Table 8: Genes and associated SNPs from IPA shown to be 




melanoma. rs401681 showing a significant p-value of 9.6*10-6 is found in this gene and 
shown to be involved in many cancers like breast cancer [106], colorectal cancer 
[106]and also melanoma [106]. 
TERT rs2736100 
TERT is a telomerase reverse transcriptase and a ribonucleoprotein polymerase which 
maintains telomerase ends located in chromosome 5. This telomerase functions as 
cellular senescence and results in shortening of telomerase. This shortening of telomeres 
are involved in the risk of cancer [102] especially melanoma [102] . rs2736100 having a 
p-value of 0.02 and MAF value of 0.486 is located in the TERT gene and recently is 
found to be involved in  glioma [107], thyroid [107], bladder [107] cancer and found in 
melanoma[107]. 
BRAF rs1267649 
BRAF is a serine/threonine kinase in Ras/Raf/MAPK signal transduction pathway [108, 
109] involved in the cell growth and is a proto oncogene. If mutated, the cell growth will 
be continuous and leads to tumorigenesis. It is located on 7q34 chromosome with 190kb 
of length. Recent studies have shown that this gene is mutated in the malignant 
melanoma (66%). Also the BRAF mutation in benign can give rise to malignant 
melanoma [110].  Meyer etal showed that rs1267649 is having a significant minor allele 
frequency of ≥0.1 and is one of the non-coding SNPs present in intron 5 in the BRAF 







IL6R is a tumor growth inhibitor for early-stage of melanoma and a growth factor for the 
tumor cells for advanced stage [104] patients with malignant melanoma when pretreated 
with serum IL6 have a very short survival time [104]. It is present in chromosome 1. IL6 
shows its activity when bound to IL6R which alters gene expression. Gu etal found that 
IL6R along with rs4845618 is involved in the melanoma risk with a p-value in hardy 
Weinberg equilibrium (HWE) is 1.04-2.84, is present in the intron region of the IL6R.  
ASIP rs1015362 
ASIP gene has a role in melanogenesis [111], when ASIP binds to MC1R it initiates 
signaling and blocks the cAMP production. This leads to the down regulation of 
eumelanogenesis (black/ brown pigments) and eventually increases pheomelanin 
(yellow/red pigments). It is located in chromosome 20 and it has shown that the 
rs1015362 has a MAF value of ≥0.1 and is located 110kb in the ASIP gene [105]. It is 
most likely associated with the sun sensitivity like sunburns. So this SNP has an effect on 
malignant melanoma. 
OBFC1 rs9420907 
OBFC1 is a subunit of alpha accessory factor that stimulates the activity of DNA 
polymerase-alpha-primase; this enzyme initiates the DNA replication. Mutations in this 
gene leads to cancer [112] . It is located in chromosome 10q24.33. This gene is present in 
the longer telomere length and has shown to be involved in cancers like melanoma as we 
as nevi and also breast cancer. rs9420907 which is present in the OBFC1 gene is 






MTAP is a gene which plays a major role in polyamine metabolism and very important in 
the salvage of adenine and methionine. The deficiency in this enzyme leads to cancer 
because the p16 tumor suppressor gene and this MTAP gene are deleted together usually. 
Located in 9p21 and 22q13 and is shown to be in the benign nevi and has a high risk of 
melanoma [54] . 
PLA2G6 rs2284063 
PLA2G6 is a phospholipase A2 gene involved in the Ras signaling pathway. Mutations in 
this gene or Ras signaling leads to the tumorigenesis. This is shown to be involved in 
benign and the risk of melanoma [54].  rs2284063 is associated with this gene in benign 
as we as melanoma [54] 
Also in IPA we found some genes that are known to be involved in melanoma, but with 
SNPs in our list which are different from the published cancer-associated SNPs. These 
are not known to be involved in melanoma so far.  So we expect that these SNPs may be 
involved in melanoma (Table 9), or may be in linkage disequilibrium with cancer-
associated SNPs. 
 GENES SNP ID(New) 
ERC2 rs732887 (B&M) 
 
LRP1B rs1372254 (B&M) 
 





SMAD3 rs9492489 (B&M) 
 
CDH13 rs11860430 (M) 
 
GRIN2B rs10772713 (B&M) 
 







Table 9 shows ERC2 [113], LRP1B[114], PDE1 [115], SMAD3 [116] repression of 
CDH13 [117] , GRIN2B [118], CLCA1 [119], GNAQ [56]. All these genes are known to 
be involved in melanoma. It may be that the SNPs associated with them are also involved 
in melanoma. 
ERC2 It is a regulator of neurotransmitter release located in chromosome 3p14.3. 
Frequent transcriptional and genetic inactivation of ERC2 can be involved in 
carcinogenesis [120]  and in melanoma it is said to be deleted [113, 121] .rs732887 is 
found in this gene with significant p-value of showing that it may have some association 
with the melanoma [113]. 
LRP1B 
This gene belongs to low density lipoprotein receptor gene family, located on 2q22.1 
chromosome. They play an important role in the cell functions and development. This 
gene is involved in the melanoma [114]. 
 
Table 9: Genes and new SNPs found in either 





PDE1 is a phosphodiesterase calmodulin dependent protein, located on chromosome 
2q32.1. The role of PDE1 gene is to degrade cGMP and cAMP. This gene regulates the 
cell proliferation, if over expressed it leads to cancer [122] and melanoma [115].  
 
SMAD3 
This gene regulates the cell death, differentiation and proliferation. This helps in the 
tumor growth in cancer. Repression of this enzyme leads to cancer [123, 124]. It is 
located in chromosome 15q22. 
CDH13 
It is a protein coding gene that regulates the cell survival, proliferation and growth and 
repression of this gene can cause tumor progression[125] and eventually to melanoma 
[117].Located on 16q23.3 chromosome. It is indirectly involved in ERK signaling in the 
melanoma [126] 
GRIN2B 
GRIN2B is a protein coding gene of glutamate receptor .Located on 12p13.1 
chromosome. It has involvement in Ras signaling pathway [127]. GRIN2B is one of the 







It is a protein coding gene located on 1p22.3. Plays an important role in cell adhesion. 
Involved in basal cell adhesion and/or in squamous epithelia.  It can act as a tumor 
suppressor in colorectal and breast cancer. It has a key role for cell adhesion in the early 
stages of lung metastasis [129]. It is a tumor suppressor gene but when mutated leads to 
melanoma [130]. 
GNAQ 
It is a Guanine nucleotide-binding protein which acts like transducer in various 
transmembrane signaling pathways. Located on 9q21.2 chromosome. It has involvement 
in MEK/MAPK and/or PI3K/AKT signaling indirectly [131]. The frequent somatic 
mutation of this GNAQ cause melanoma [56] . It is a therapeutic biomarker for the uveal 
melanoma [56]. 
However the SNPs associated with all these genes were so far not shown in the literature 
that they involved in cancer/disease. But these SNPs have significant chi-square p-value 
with in the range of ≥1.08E-22 & ≤5.30E-26, which indicates that they may be involved in 









Flowchart summarizes the sequential steps in filtering and analyzing the SNPs in both 






• Generated 63 CEL files (21 benign & 42 melanoma) 
APT 
• Input : 63 CEL files 
• Sample QC step : Figure 10 
GTC 
• Input : 63 CEL files 
• Sample QC and generated genotypes (63 CHP files) : 
Figure 12 
• Output : 63 CHP files 
PGS 
• Input : 63 CHP files 
• Sample and SNP QC followed by association analysis 
between SNPs in both benign & melanoma and allele  
frequency differences with p-value ≤0.05 : Figure 13  
• Output: SNPs and genes list with p-values of both 
benign and melanoma 
IPA 
• Input : Genes list  filtered with strict p-value 
(≤1.08E-22 & ≥5.30E-26)  
• Core analysis  
• Output : List of genes along with SNPs associaed 
with melanoma (Table 8) that are already in 
literature and also list of genes with new SNPs found 
in melanoma (Table 9) which have to be validated 






This part summarizes the findings and the problems we solved in the thesis work and 
possible future directions. 
In this thesis, we showed that the type of DNA extraction method does have an effect on 
DNA quality, since getting DNA from FFPE tissues is always challenging even though it 
has several advantages like stable for decades, can use very old FFPE blocks, vast 
number of blocks available, easily accessible and easy handling and used especially in the 
diagnosis of cancer. Column is a solid-phase extraction and phenol-chloroform method is 
liquid-liquid extraction, both these methods require more sections of FFPE tissues, also 
these methods de-paraffinize the tissues using organic solvents which can later interfere 
with the DNA purification process and inhibit PCR reaction. On the other hand, AFA 
which is solid-phase extraction that requires less number of tissue sections compared to 
other two methods. This AFA method de-paraffinizes the tissues using acoustic energy 
without any organic solvent xylene, which is commonly used for removing paraffin in 
other two extraction methods. Our results show that the use of xylene is associated with 
decreased amplicon length in PCR and increased RAPD PCR failure rate [132].  Any 
sample shown less than 300 base pair length by RAPD PCR is considered as failure here.  
It is very important to have greater than 300 base pair length of amplicon for downstream 




Although xylene-free extraction method have shown to be successful, they are not 
standardized to reproducibility and safety guidelines for using clinically [134, 135].  
 
Also in the AFA method, tissue rehydration takes place during the de-paraffinization 
process that allows proper protein digestion and complete reverse-crosslinking, 
supporting efficient purification of DNA [136].  
 The improved DNA quality from FFPE tissues is very important for the array CGH 
analysis. One of the studies showed that the quality and quantity of FFPE DNA is 
assessed by using Nanodrop, 260/230, 260/280 ratios and gel electrophoresis for looking 
into genomic DNA for hybridizing successfully them to the microarrays. However they 
did not perform PCR to know the degradation of FFPE DNA samples [137]. Here but in 
our studies we did perform RAPD PCR along with Nanodrop, qubit and gel 
electrophoresis to assess the quality of the samples. Of all the three extraction methods, 
AFA method showed improvements in the FFPE DNA quality. Ours is the first study to 
compare AFA with column and phenol methods. 
 AFA samples were performed with SNP 6.0 protocol, successfully hybridized to the 
microarrays and were compared against the column samples, the phenol samples were 
not used because they did not pass the initial QC steps in the SNP 6.0 protocol. The AFA 
samples showed better initial quality control metrics like the optimum amplicon length in 
the PCR, enough concentrations to proceed to next steps, good fragmentation length so 
that they can hybridize to the microarrays successfully. These microarrays of AFA and 
column samples when analyzed with the APT fragment length analysis, AFA samples 




method of FFPE DNA does help in improving the quality of the DNA for hybridizing 
onto the microarrays. The raw array data that was generated with these AFA samples 
after SNP 6.0 protocol were genotyped using genotyping console and then the SNPs were 
filtered and analyzed in Partek Genomics Suite. The SNPs with their genes from Partek 
were confirmed in the Ingenuity pathway analysis tool. Some of the SNPs along with 
their genes in our list were already shown in literature in Table 8 that they are involved in 
the melanoma and some of them were shown in our benign samples. BRAF along with 
rs1267649 is one of the most common genes and SNPs associated with melanoma is also 
shown in our list.  Also found some new SNPs in our list that were not shown to be 
involved in the melanoma so far but the genes associated with these SNPs. Some of these 
SNPs are found both in the melanoma and benign samples and some are just in the 
melanoma. Benign nevi which are non-cancerous and not metastatic can give rise to 
malignant melanoma when exposed to certain risk factors [54] whereas malignant 
melanoma is a metastatic cancer. So these findings suggest that the new SNPs around the 
known genes may also be involved in the melanoma and also the SNPs that are in the 
benign nevi may give rise to the malignant melanoma. Recent findings showed that the 
nevi, which are a risk factor for melanoma, have distinct patterns of genes and SNPs. 
These findings may help in identifying the subsets of nevi that have distinct biological 
features and the risk phenotypes in the individuals, however more studies have to be done 
to confirm their findings [138].The project future directions include: Increase the size of 
the samples, perform genotyping analysis separately for benign and melanoma with 
normal samples. Find whether the SNPs found in our study are driver mutations or not by 




whether the genes we found in our data that are involved in melanoma are also involved 
in other cancers. Perform Next Generation Sequencing (NGS) to generate genotype data. 
SNPs obtained from clinical specimens that are statistically significant in malignant 
melanoma and/or benign nevi, may represent the functional genes involved in melanoma. 
Significant SNPs in benign nevi and/or melanoma that may predispose to malignant 
melanoma can improve vigilance by encouraging detection of the melanoma in the early 
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